08.29.23 -- The Global Landscape For Synthetic Biology In Biopharma Through 2035

Precision powder microdosing makes it possible to quickly get formulations to the clinic, saving time, money, and use of limited APIs.

This article provides general guidance on how to convert an existing ELISA assay to a Biacore SPR assay and, by doing so, shows how you can get results in less than half the time compared with ELISA.

See how the team developed analytical methods to support preclinical and future GMP production under tight timelines.

Treatments for glioblastoma multiforme (GBM) are in high demand. Learn more about the new possibilities for increased dosing and diffusion capabilities offered by nanoformed APIs.

Kimberly Shepard, Ph.D., principal engineer in R&D, addresses the challenges associated with spray-drying late-stage lung cancer treatments, including proteins, peptides, and mAbs.